已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Time to reconsider the perception and management of hypertensive heart disease

医学 心力衰竭 疾病管理 感知 高血压性心脏病 心脏病学 疾病 梅德林 内科学 心脏病 重症监护医学 神经科学 帕金森病 政治学 法学 生物
作者
Javier Dı́ez,Giuseppe Rosano,Javed Butler
出处
期刊:European Journal of Heart Failure [Oxford University Press]
卷期号:25 (4): 450-453 被引量:4
标识
DOI:10.1002/ejhf.2811
摘要

Heart failure (HF) is a global pandemic. Its prevalence is increasing with the aging of the population, with improved treatment of ischemic heart disease (IHD) and the availability of effective evidence-based therapies that prolong survival of patients with HF. Despite the age-standardized stable worldwide prevalence of systemic arterial hypertension, but considering that the rates of hypertension control with treatment have worsened in recent years, hypertension remains one of the main causes of HF with a global impact. In the last two decades, the presence of hypertension has increased in incident cases of HF either with reduced (HFrEF) or with preserved ejection fraction (HFpEF).1 Additionally, the lifetime risk of HF is higher in people with hypertension than in those with normal blood pressure (BP), especially in women and the elderly.1 On the other hand, the incidence of de novo HF in 23 hypertension trials involving 193 424 patients was 28.9% (n = 7171) of the all major cardiovascular events reported.2 Therefore, HF continues to represent a major concern in hypertension management. Hypertensive heart disease (HHD) can be defined as the cardiomyopathy that results from the response of the myocardium to the biomechanical stress imposed on the left ventricle by progressively increasing BP. HHD encompasses a broad spectrum including asymptomatic left ventricular hypertrophy (LVH) (either a concentric or an eccentric pattern) and clinical HF (either HFpEF or HFrEF). Epidemiological evidence supports that HHD is a major factor responsible for the increased risk of HF in the overall population. First, the global age-standardized prevalence rate of HHD has increased over the last 30 years, especially in women and older people.3 Second, at the global population level, HHD represents the second cause of prevalent HF after IHD, but in adults aged 25 to 69 years, it accounts for the largest share of all causes of HF.4 While the population-attributable risk of IHD-related HF was higher in high-income geographic areas, the HHD-related risk was higher in low- and middle-income areas.3, 4 Third, after 2011, age-adjusted mortality rate for HF and HHD increased at a faster rate than for HF attributable to other subtypes of heart disease.5 HHD can no longer be considered as the simple result of the hypertrophy of cardiomyocytes in response to pressure overload leading to the development of LVH, responsible for subsequent cardiac dysfunction and HF. Indeed, a review of 30 echocardiographic studies including 37 700 treated and untreated hypertensive patients showed that LVH was absent in approximately two-thirds of untreated patients despite having chronic high BP.6 Furthermore, in a meta-regression analysis of 14 studies including 12 809 hypertensive patients, treatment-induced regression of LVH was found not to prevent new-onset HF.7 Therefore, the opinion has emerged that in patients with HHD changes in myocardial tissue that lead to its histological remodeling may result in alterations in cardiac function, perfusion and electrical activity contributing to increased risk of HF (Table 1).8 Both decreased energetic efficiency and mechanical force of hypertrophic cardiomyocytes and increased apoptosis with reduced numbers of viable cardiomyocytes impair systolic function in the human hypertensive heart. In addition, diffuse reactive interstitial fibrosis (often accompanied by low-grade perivascular inflammation) increases the passive stiffness of the extracellular matrix, contributing to increased left ventricular (LV) pressure and impaired filling during diastole, and restricts stretching of cardiomyocytes in diastole, reducing their length-dependent force generation in systole. In this sense, increases in cardiomyocyte apoptosis9 and interstitial deposition of type I collagen fibres10 are observed in endomyocardial biopsies from patients with HHD and HF compared to patients with HHD without HF. The associations of increased apoptosis and fibrosis with adverse LV remodeling in these studies support a potential role for these lesions in the transition from subclinical HHD to clinically manifest HF.9, 10 More recently, attention has focused on changes in the coronary blood and lymphatic microcirculations in the hypertensive heart that may have a deleterious impact on cardiac function. In addition to functional changes (e.g., vasomotor dysregulation and proinflammatory-profibrogenic activation of the endothelium), anatomic changes (e.g., increased medial thickness-to-lumen ratio and decreased maximum cross-sectional area of pre-arterioles and arterioles, and decreased vascular density due to capillary rarefaction) have been described in patients with HHD.8 These changes make the myocardium a permanently ischemic tissue that facilitates the death of cardiomyocytes and reparative fibrosis and, consequently, HF. Supporting this possibility, Brown et al.11 demonstrated in hypertensive patients with HFrEF and without coronary artery disease who underwent positron emission tomography (PET) myocardial perfusion imaging that a low LV myocardial blood flow-to-mass ratio (indicative of a supply/demand mismatch) was associated with greater LV mass, worse LV systolic function, and elevated levels of circulating cardiac troponins T and I. Interestingly, a lower LV blood flow-to-mass ratio was independently associated with hospitalization for incident HF, among other adverse clinical outcomes.11 On the other hand, insufficient cardiac lymphangiogenesis and lymphatic dysfunction may facilitate myocardial edema and contribute to inflammation and fibrosis in the hypertensive heart.8 Importantly, HHD is characterized by myocardial remodeling, namely interstitial fibrosis, not only in the left ventricle but also the left atrium.8 Left atrial remodeling may culminate in atrial fibrillation and atrial contractile dysfunction, thus contributing to the development of HF. Finally, right heart myocardial remodeling may develop in HHD independently of the influence of lung disease or pulmonary hypertension and may affect right ventricular and right atrial function. Therefore, it is increasingly apparent that HHD encompasses a range of cardiac alterations beyond macroscopic LVH, characterized by microscopic myocardial lesions and subsequent functional changes that affect the heart as a whole. In the origin of these alterations must be also implicated mechanisms typical of hypertension as a systemic process that affects target organs other than the heart (e.g., ventricular–arterial uncoupling due to stiffness of the aorta and large arteries). The growing HF burden of HHD represents an unmet medical need. Therefore, HHD requires an innovative diagnostic approach based on phenotyping of myocardial tissue remodeling to identify high-risk HF patients and personalize treatment to regress remodeling and prevent the transition to HF (Figure 1). As myocardial remodeling cannot be routinely evaluated through endomyocardial biopsies, it is necessary to investigate the clinical utility of combining biomarkers. On the one hand, circulating biomarkers that identify the molecular and histological signatures of the remodeled myocardium (e.g., proteins, non-coding RNAs, metabolites and/or epigenetic modifications).12 On the other hand, advanced imaging-derived biomarkers that characterize myocardial tissue (e.g., parameters assessed with LV strain, cardiovascular magnetic resonance [CMR] imaging, computed tomography or PET of myocardial perfusion).13 Two recent studies focused on imaging and circulating biomarkers of myocardial interstitial fibrosis may support this novel approach. In asymptomatic hypertensive patients, myocardial interstitial fibrosis on CMR imaging with non-ischemic late gadolinium enhancement (LGE) was associated with greater LV mass, worse function, and elevated circulating levels of N-terminal pro-B type natriuretic peptide (NT-proBNP).14 Importantly, non-ischemic LGE was also associated with adverse outcomes, including first hospitalization for HF.14 On the other hand, in individuals at risk for HF (including over 78% with chronic arterial hypertension), a circulating biomarker of myocardial interstitial fibrosis (i.e., serum C-terminal type I collagen propeptide [PICP]) was associated with greater LV mass, worse LV diastolic function, and elevated levels of circulating NT-proBNP.15 Of note, a decrease in serum PICP with spironolactone treatment was associated with improvements in LV diastolic dysfunction (e.g., reduction in diastolic mitral inflow velocity to early diastolic mitral annulus velocity [E/e' ratio]).15 Presumably, using a multimodal approach supplemented with machine learning and artificial intelligence applications, distinct myocardial remodeling phenotypes with heterogeneous pathophysiology and consequently variable HF risk and therapeutic requirements will be identified in patients with HHD. To this aim, multinational collaborative efforts are needed to provide large independent cohorts with the simultaneous assessment of the panels of biomarkers and develop and validate algorithms to support clinical decision-making. HF attributable to chronic hypertension is one of the greatest threats to the society today, and will become even more so in the future, especially in certain geographic areas of the world and for some population groups. Our collective understanding of HHD remains incomplete, which helps fuel the risk for HF. Therefore, translational research is urgently necessary to learn more about the mechanisms leading to changes at cellular and tissue levels that induce myocardial remodeling in patients with HHD. In addition, personalized multiple biomarker-guided therapeutic strategies based on stratification of HHD patients according to their remodeling phenotype should be designed and evaluated in future clinical trials to prevent HF in these patients. Physicians, basic scientists, public health systems, insurance companies, pharmaceutical companies, patients, and regulatory bodies, need to be involved in this paradigm shift. Conflict of interest: JD is consultant to AstraZeneca, Bayer, Vifor Pharma and Glaxo, Smith and Kline. JB is consultant to Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Sequana Medical, and Vifor Pharma.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被依依加油发文章采纳,获得10
1秒前
1秒前
山有树完成签到 ,获得积分10
4秒前
云梦泽完成签到 ,获得积分10
6秒前
6秒前
allover完成签到,获得积分10
13秒前
judy发布了新的文献求助10
13秒前
14秒前
多鱼完成签到,获得积分10
15秒前
21秒前
jamesmo发布了新的文献求助30
22秒前
yu完成签到 ,获得积分10
23秒前
jcz完成签到,获得积分10
24秒前
25秒前
科研通AI6.4的应助被微解感染采纳,获得10
25秒前
JIE完成签到,获得积分10
29秒前
孤独的万恶完成签到 ,获得积分10
34秒前
Xi发布了新的文献求助60
35秒前
ni完成签到 ,获得积分20
35秒前
友好灵阳完成签到 ,获得积分10
36秒前
无花果的应助被2567285426采纳,获得10
37秒前
jamesmo完成签到,获得积分10
37秒前
yueqi完成签到,获得积分10
38秒前
愉快的真的应助被屈屈采纳,获得100
38秒前
铁打的雨点完成签到,获得积分10
39秒前
40秒前
小马完成签到,获得积分10
41秒前
zyyyyyy发布了新的文献求助10
41秒前
syvshc的应助被微解感染采纳,获得10
41秒前
合适雨完成签到,获得积分10
42秒前
dudu完成签到 ,获得积分10
43秒前
wanci的应助被lSj采纳,获得10
43秒前
sshuo发布了新的文献求助10
44秒前
言默完成签到,获得积分20
45秒前
趣多多发布了新的文献求助10
45秒前
47秒前
47秒前
何在完成签到,获得积分10
48秒前
54秒前
BugerKing完成签到 ,获得积分10
55秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194853
求助须知:如何正确求助?哪些是违规求助? 9580631
关于积分的说明 21872074
捐赠科研通 7794509
什么是DOI,文献DOI怎么找? 3437779
关于科研通互助平台的介绍 2561109
邀请新用户注册赠送积分活动 2484488